Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 5945Pancreatic Neoplasms 3561Carcinoma, Hepatocellular 3271Stomach Neoplasms 3056Colonic Neoplasms 2327Rectal Neoplasms 2191Esophageal Neoplasms 1800Liver Neoplasms 1246Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 870Carcinoma, Non-Small-Cell Lung 792Lung Neoplasms 744Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 584Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 303Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

durvalumab 1Surgical Procedures, Operative 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cisplatin 1Capecitabine 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Resectable Intrahepatic Cholangiocarcinoma × Gastrointestinal × Clear all
NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

National Cancer Institute (NCI)

Phase 2 Recruiting
27 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT05265208 2025-08-06

SIROCHO

Center Eugene Marquis

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡